ABCC8-related maturity-onset diabetes of the young: switching from insulin to sulphonylurea therapy: how long do we need for a good metabolic control?-Reference-Cited by-同舟云学术

ABCC8-related maturity-onset diabetes of the young: switching from insulin to sulphonylurea therapy: how long do we need for a good metabolic control?

Published:2023-04-17 Issue:0 Volume:0 Page:
ISSN:0334-018X
Container-title:Journal of Pediatric Endocrinology and Metabolism
language:en
Short-container-title:

Author:

Evin Ferda¹^ORCID,Işık Esra²^ORCID,Onay Hüseyin³^ORCID,Özen Samim¹^ORCID,Darcan Şükran¹^ORCID,Gökşen Damla¹^ORCID

Affiliation:

1. Faculty of Medicine, Department of Pediatric Endocrinology and Diabetes , Ege University , İzmir , Türkiye

2. Faculty of Medicine, Department of Pediatric Genetics , Ege University , İzmir , Türkiye

3. Multigen Genetic Diseases Diagnosis Center , Izmir , Türkiye

Abstract

Abstract Objectives Activating variants of the ABCC8 gene cause neonatal diabetes or maturity-onset diabetes of the young (MODY). We report three cases of MODY type 12 caused by variants in the ABCC8 encoding sulphonylurea receptor 1, and the experience of switching from insulin therapy to sulphonylurea therapy. Case presentations We describe a 12.5-year-old girl with permanent neonatal diabetes mellitus, and two diabetes mellitus cases with variants in the ABCC8 gene. Two of these cases were successfully switched from subcutaneous insulin to oral glibenclamide, with a marked improvement in glycemic control. In permanent neonatal diabetes case, glibenclamide dose was progressively increased to achieve a full dose (2 mg/kg/day) in 9 days. Nine months after starting oral sulphonylurea therapy, her blood glucose control dramatically improved and insulin therapy was discontinued. Conclusions We conclude that patients with ABCC8 gene variants can successfully switch from insulin to sulphonylureas.

Publisher

Walter de Gruyter GmbH

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Pediatrics, Perinatology and Child Health

Link

https://www.degruyter.com/document/doi/10.1515/jpem-2022-0642/pdf

Reference19 articles.

1. Lachance, CH. Practical aspects of monogenic diabetes: a clinical point of view. Can J Diabetes 2016;40:368–75. https://doi.org/10.1016/j.jcjd.2015.11.004.

2. Gloyn, AL, Pearson, ER, Antcliff, JF, Proks, P, Bruining, GJ, Slingerland, AS, et al.. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838–49. https://doi.org/10.1056/nejmoa032922.

3. Huopio, H, Otonkoski, T, Vauhkonen, I, Reimann, F, Ashcroft, FM, Laakso, M. A new subtype of autosomal dominant diabetes attributable to a mutation in the gene for sulfonylurea receptor 1. Lancet 2003;361:301–7. https://doi.org/10.1016/s0140-6736(03)12325-2.

4. Globa, E, Zelinska, N, Mackay, DJG, Temple, KI, Houghton, JAL, Hattersley, AT, et al.. Neonatal diabetes in Ukraine: incidence, genetics, clinical phenotype and treatment. J Pediatr Endocrinol Metab 2015;28:1279–86. https://doi.org/10.1515/jpem-2015-0170.

5. Alaei, MR, Akbaroghli, S, Keramatipour, M, Alaei, A. A case series: congenital hyperinsulinism. Int J Endocrinol Metab 2016;14:e37311. https://doi.org/10.5812/ijem.37311.